Clot Stiffness Measured By Seer Sonorheometry As a Marker Of Poor Prognosis In Hospitalized COVID-19 Patients.
Clin Appl Thromb Hemost 2022;
28:10760296221112085. [PMID:
35903939 PMCID:
PMC9340415 DOI:
10.1177/10760296221112085]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
A high risk of thrombotic complications has been observed among severely ill
COVID-19 patients. Viscoelastic tests (VET) have shown a hypercoagulable profile
in these patients, although so far there is no clear evidence on the use of
these tools as predictors of risk in the clinical course of patients. In this
study we aimed to evaluate the association between Quantra® sonorheometry VET
parameters, standard coagulation tests and inflammatory markers in 69 patients
with COVID-19 on hospital admission with disease severity and outcome.
Inflammatory markers were elevated in a high percentage of patients, as were
coagulation-related parameters such as fibrinogen and D-dimer levels. Quantra®
sonorheometry analysis revealed increased clot stiffness (CS), especially due to
increased fibrinogen contribution (FCS) in 63.7%. Analysis of clot stability to
lysis (CSL) on the Quantra showed a value of 100%, suggesting hypofibrinolysis,
in 32.4%. Age > 65 years, elevated values of fibrinogen, D-dimer, LDH,
increased CS and CSL were significantly associated with worsening disease. The
combination of elevated FCS and D-dimer values showed a particularly high
prognostic value in distinguishing patients with severe symptomatology. In
conclusion, FCS measured by Quantra® system and its combination with D-dimer
could be established as a powerful tool to identify poor prognosis in COVID-19
patients on hospital admission.
Collapse